1. Volume 75, Pages S55-S58 (February 2009)
A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura 
Stephen R Foley, Kathryn Webert, Donald M Arnold, Gail A Rock, William F Clark, David Barth, David M Sutton 
Kidney International 
Volume 75, Pages S55-S58 (February 2009)
DOI: /ki
Copyright © 2009 International Society of Nephrology Terms and Conditions

2. Figure 1
Preliminary evidence indicating the efficacy of rituximab. Both patients with relapsed disease and those who are refractory may derive benefit. CRP, cryo-poor plasma; FFP, fresh frozen plasma; LDH, lactate dehydrogenase; po, per os; TPE, therapeutic plasma exchange; TTP, thrombocytopenic purpura.
Kidney International  , S55-S58DOI: ( /ki )
Copyright © 2009 International Society of Nephrology Terms and Conditions

3. Figure 2
Trial schema. Arrows represent rituximab infusions, green stoppered red tubes are routine blood testing, green and white tubes are symbols for ADAMTS13 inhibitor testing and plasma bags symbol for rituximab levels in plasma removed by plasma exchange. CAG, Canadian Apheresis Group; TTP, thrombocytopenic purpura.
Kidney International  , S55-S58DOI: ( /ki )
Copyright © 2009 International Society of Nephrology Terms and Conditions